JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Insulet Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

159.87 -12.56

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

157.91

Max

182.75

Pagrindiniai rodikliai

By Trading Economics

Pajamos

14M

102M

Pardavimai

78M

784M

P/E

Sektoriaus vid.

53.957

67.147

Pelno marža

12.962

Darbuotojai

5,400

EBITDA

17M

177M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+77.06% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4B

13B

Ankstesnė atidarymo kaina

172.43

Ankstesnė uždarymo kaina

159.87

Naujienos nuotaikos

By Acuity

24%

76%

82 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Insulet Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 23:53; UTC

Uždarbis

Naver Posts Weaker First-Quarter Earnings

2026-04-29 23:41; UTC

Karštos akcijos

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

2026-04-29 23:55; UTC

Uždarbis

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-29 23:54; UTC

Uždarbis

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

2026-04-29 23:52; UTC

Uždarbis

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

2026-04-29 23:51; UTC

Uždarbis

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

2026-04-29 23:51; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

2026-04-29 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

2026-04-29 23:22; UTC

Uždarbis

China Longyuan 1Q Net CNY1.70B, Down 14%

2026-04-29 23:22; UTC

Uždarbis

China Longyuan: Power Generation Down 2.9% as of End-March

2026-04-29 23:20; UTC

Uždarbis

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

2026-04-29 23:20; UTC

Uždarbis

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss Narrows>000002.SZ

2026-04-29 23:18; UTC

Uždarbis

Naver1Q Net Profit Missed FactSet-Compiled Consensus

2026-04-29 23:17; UTC

Uždarbis

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

2026-04-29 23:13; UTC

Uždarbis

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

2026-04-29 23:12; UTC

Uždarbis

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

2026-04-29 23:04; UTC

Uždarbis

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

2026-04-29 23:04; UTC

Uždarbis

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Akcijų palyginimas

Kainos pokytis

Insulet Corp Prognozė

Kainos tikslas

By TipRanks

77.06% į viršų

12 mėnesių prognozė

Vidutinis 323.79 USD  77.06%

Aukščiausias 435 USD

Žemiausias 220 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Insulet Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

16

Pirkti

3

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

252.29 / 259.38Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

82 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat